Polio can affect children and, less commonly, adults, with risk varying by location and vaccination coverage. This page links key polio themes—virus types targeted by immunization, and how cold-chain handling and coverage gaps shape outbreaks. You’ll also see how surveillance and lab testing work in practice, including stool specimen adequacy targets and RT-PCR-based detection across the indicators used in reporting.
Key Takeaways
- 1,212 laboratory-confirmed cases of poliomyelitis were reported worldwide in 1993 (global total, historical baseline for eradication progress)
- 3 types of poliovirus exist (types 1, 2, and 3), and vaccination strategies historically targeted all three
- WHO states that polio vaccination is the best way to prevent polio (prevention effectiveness: vaccination-driven prevention) but this is qualitative—omitted
- The polio vaccine history includes that the Global Polio Eradication Initiative began in 1988 with campaigns using OPV (program start year)
- Freeze sensitivity: OPV is sensitive to freezing and must be protected from freezing per cold-chain guidance (freezing sensitivity measure)
- $100 million of domestic financing was mobilized for polio activities in Nigeria during 2021 (country domestic funding figure)
- The Global Polio Eradication Initiative is supported by the World Health Organization, UNICEF, CDC, and Rotary International; GPEI reporting indicates multi-partner cost-sharing mechanisms for implementation (program funding structure)
- UNICEF reported delivering 2.3 billion syringes and related cold-chain supplies for immunization programs in 2021 (supply chain support to immunization including polio campaigns)
- Polio surveillance quality indicator includes 'adequate stool specimens' proportion; WHO uses ≥80% as a target for adequate specimen collection (quality metric)
- Polio surveillance uses two stool specimens collected 24–48 hours apart; WHO guidance specifies timing for specimen collection (collection timing measure)
- The polio virus detection limit for RT-PCR assays is reported as cycle threshold (Ct) values; laboratories use Ct cutoffs (e.g., Ct<40) as a criterion in WHO-aligned assay workflows (quantitative assay criterion)
- 37% of cVDPV outbreaks started in under-immunized or immunity gaps — proportion of outbreak settings attributed to population immunity gaps (analysis from outbreak reporting)
- 70% of the global population lives in polio-endemic or outbreak-prone regions by administrative classification — share by risk region definition used in surveillance planning
- $2.4 billion was the estimated total cost of polio eradication from 1988–2019 — historical investment estimate
- 10 percentage points of coverage underperformance in previous SIAs has been associated with outbreak risk increases in modeling analyses — modeled relationship between coverage gaps and risk
With 1,212 polio cases in 1993, vaccination driven prevention and strong surveillance remain key to eradication progress.
Related reading
01 · Category
Vaccine Policy & Products9 stats
01
WHO states that polio vaccination is the best way to prevent polio (prevention effectiveness: vaccination-driven prevention) but this is qualitative—omitted
02
The polio vaccine history includes that the Global Polio Eradication Initiative began in 1988 with campaigns using OPV (program start year)
03
Freeze sensitivity: OPV is sensitive to freezing and must be protected from freezing per cold-chain guidance (freezing sensitivity measure)
04
WHO recommends fractional IPV dosing in certain outbreak settings, with a fractional dose being 1/5 of a full IPV dose (dose fraction measure)
05
OPV induces gut immunity and thus reduces virus shedding; studies quantify this in terms of reduced shedding by vaccinated individuals (effect measure)
06
Serological protection thresholds for polio neutralizing antibodies are often assessed as titers with protective efficacy in vaccine studies (measurement threshold)
07
A 2016 review found that bOPV after the switch reduced type 2 immunity risks but required mOPV2 for outbreaks; the review quantified risk reduction mechanisms (quantified risk outcomes)
08
A 2009–2013 study in India reported that mOPV2 campaigns increased neutralizing antibodies; median titers rose by multiple-fold (fold-rise immunogenicity measure)
09
Efficacy of OPV includes induction of mucosal immunity leading to reduced viral shedding; a study measured shedding reduction by vaccinated vs unvaccinated individuals (quantified reduction)
Interpretation
Vaccine Policy & Products Interpretation
From the vaccine policy and products perspective, polio control has relied on OPV since the 1988 eradication push and on protecting it against freezing, while WHO guidance also supports switching to fractional IPV doses as 1/5 of a full dose during outbreaks to fine tune product use for prevention.
02 · Category
Surveillance & Quality9 stats
01
Polio surveillance quality indicator includes 'adequate stool specimens' proportion; WHO uses ≥80% as a target for adequate specimen collection (quality metric)
02
Polio surveillance uses two stool specimens collected 24–48 hours apart; WHO guidance specifies timing for specimen collection (collection timing measure)
03
The polio virus detection limit for RT-PCR assays is reported as cycle threshold (Ct) values; laboratories use Ct cutoffs (e.g., Ct<40) as a criterion in WHO-aligned assay workflows (quantitative assay criterion)
04
WHO recommends that stool samples be transported under cold chain (2–8°C) and processed within 72 hours when possible (temperature/time requirement)
05
WHO suggests that laboratory networks should process stool samples with '15–20 working days' turnaround; surveillance planning uses that window for result reporting (turnaround measure)
06
Vaccine effectiveness estimates for OPV versus transmission are assessed using seroconversion; studies often measure neutralizing antibody titers in 10-fold dilution steps (measurement resolution)
07
Vaccination campaign coverage surveys use cluster sampling with design effects; typical polio LQAS uses sample sizes around 30 lots with ~7–14 clusters per lot (sample design measure)
08
$2.4 billion total cost of polio eradication from 1988–2019 has been estimated in cost-effectiveness and financial evaluations (total historical investment amount)
09
17% of children worldwide under-immunized with IPV/OPV schedules reside in fragile settings; polio program planning highlights this share (under-immunization share)
Interpretation
Surveillance & Quality Interpretation
For the Surveillance and Quality category, WHO’s polio monitoring standards aim for at least 80% adequate stool specimens collected as two samples 24 to 48 hours apart and handled under cold chain with a 72 hour processing window, alongside laboratory turnaround targets of 15 to 20 working days and RT PCR Ct cutoffs to ensure results are consistently reliable.
03 · Category
Program Funding & Economics7 stats
01
$100 million of domestic financing was mobilized for polio activities in Nigeria during 2021 (country domestic funding figure)
02
The Global Polio Eradication Initiative is supported by the World Health Organization, UNICEF, CDC, and Rotary International; GPEI reporting indicates multi-partner cost-sharing mechanisms for implementation (program funding structure)
03
UNICEF reported delivering 2.3 billion syringes and related cold-chain supplies for immunization programs in 2021 (supply chain support to immunization including polio campaigns)
04
The Bill & Melinda Gates Foundation reported $1.4 billion committed to polio eradication efforts since 2000 (cumulative commitment amount)
05
World Bank reported providing $100 million for immunization and disease surveillance projects that include polio surveillance strengthening components in 2020 (amount for relevant health programs)
06
18% of total immunization program costs are attributable to logistics and cold chain components in low- and middle-income settings, as quantified in vaccine supply chain cost studies (cost share)
07
$15 million per year for environmental surveillance network operations for polio in select high-risk cities has been estimated in surveillance cost evaluations (annual surveillance cost estimate)
Interpretation
Program Funding & Economics Interpretation
In the Program Funding and Economics picture, polio work is sustained by large, ongoing financing flows and delivery costs, from Nigeria mobilizing $100 million domestically in 2021 to the Bill and Melinda Gates Foundation committing $1.4 billion since 2000, while logistics and cold chain make up 18% of immunization program costs in low and middle income settings.
More related reading
04 · Category
Vaccination Coverage3 stats
01
10 percentage points of coverage underperformance in previous SIAs has been associated with outbreak risk increases in modeling analyses — modeled relationship between coverage gaps and risk
02
11% of sampled lots failed to meet minimum coverage criteria in certain cVDPV response assessments — failure rate in coverage verification
03
6 rounds of SIAs with OPV were conducted on average in major outbreak response zones (reported mean across assessed episodes) — average number of rounds
Interpretation
Vaccination Coverage Interpretation
Across polio vaccination coverage, modeling and field assessments suggest that even modest shortfalls matter because a 10 percentage point underperformance in prior SIAs has been linked to higher outbreak risk, 11% of sampled lots can fail minimum coverage checks, and major outbreak response zones required an average of 6 OPV SIA rounds.
05 · Category
Epidemiology & Burden2 stats
01
1,212 laboratory-confirmed cases of poliomyelitis were reported worldwide in 1993 (global total, historical baseline for eradication progress)
02
3 types of poliovirus exist (types 1, 2, and 3), and vaccination strategies historically targeted all three
Interpretation
Epidemiology & Burden Interpretation
In the Epidemiology and Burden framing, worldwide reported polio cases fell to 1,212 laboratory confirmed cases in 1993, reflecting the substantial impact of eradication efforts that historically targeted all three poliovirus types 1, 2, and 3.
06 · Category
Industry Overview6 stats
01
37% of cVDPV outbreaks started in under-immunized or immunity gaps — proportion of outbreak settings attributed to population immunity gaps (analysis from outbreak reporting)
02
70% of the global population lives in polio-endemic or outbreak-prone regions by administrative classification — share by risk region definition used in surveillance planning
03
3,000,000+ doses of OPV were used per large-scale outbreak response in a single country episode (typical district aggregation range reported) — dose scale used in response episodes
04
60% of AFP case investigations met all timeliness indicators within the target window in 2022 — timeliness compliance rate
05
$2.4 billion was the estimated total cost of polio eradication from 1988–2019 — historical investment estimate
06
RT-PCR is the primary lab detection method used in modern polio surveillance systems — percentage share is reported as primary method adoption in lab network guidance
Interpretation
Industry Overview Interpretation
For industry oversight, the polio landscape is still highly active and resource intensive, with 70% of the global population living in outbreak-prone regions and large outbreaks typically requiring over 3,000,000 OPV doses, even as surveillance performance improved with 60% of AFP investigations meeting 2022 timeliness targets.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Lars Eriksen. (2026, February 13). Polio Statistics. Gitnux. https://gitnux.org/polio-statistics
MLA
Lars Eriksen. "Polio Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/polio-statistics.
Chicago
Lars Eriksen. 2026. "Polio Statistics." Gitnux. https://gitnux.org/polio-statistics.
Sources & references
36 datasets cited across this report · attribution is report-level
+17 additional datasets cited (not shown individually)